Abstract
More money is spent advertising alcohol than any other product. For some, it
like gambling and cigarettes are pleasant distractions, yet for others they
are the generators of unbearable cravings and the cause of considerable
distress. For them their addition is a disease. According to a new report by
visiongain - Anti-addiction Therapies, 2006-2011 - society is crying out for
solutions. Which pharmaceutical companies are now aiming to be that cure? This
report will tell you.
Doctors and concerned specialists have long maintained a behavioural- based
approach to treating addiction is the most effective treatment programme.
Suggested pharmaceutical solutions simply did not work. That is it
seems...until now. Two leading pharmaceutical companies have developed novel
drugs that could revolutionise the treatment of obesity and nicotine
addiction. And what is more, those drugs could save health authorities
millions of dollars. With the pharmaceutical industry anxiously seeking the
next blockbuster product, it is hardly surprising that Chantix and Acomplia
are generating so much interest. Are these drugs set to shift the focus of the
pharmaceutical industry? Find out today.
Will these drugs really make much of a difference for such complex disorders?
Is this not just the industry wary of decline seizing an opportunity to make
money? Visiongain's report - Anti-addiction Therapies, 2006-2011 - assesses
the currently available drugs, analysing which pipeline drugs appear to fit
unmet needs best. This report also examines which pharmaceutical companies are
likely to be market leaders by 2011.
Pfizer's Chantix, for the treatment of nicotine addiction, and Sanofi-Aventis'
Acomplia might provide not only much needed effective relief to thousands of
addicts, but could also help develop and drive a market as Viagra did for
erectile dysfunction. Markets that are currently worth $1 billion could
multiply several-fold within the foreseeable future.
"If Chantix and Acomplia prove to be as effective, but with the minimal side
effect profiles that Pfizer and Sanofi-Aventis claim, then we could see
significant development in these treatment markets," commented visiongain
market analyst and author of this latest report, Tristan Heath. This optimism
is based upon the increasing incidence of obesity throughout the developed
world and the stated wish of 70% of smokers to quit tobacco. Health
authorities throughout the developed world have placed these health issues as
top priorities. This is a potential market you cannot afford to ignore.
Imagine the potential success your company could aachieve through being
informed of this market now.
Treatment can be tailored to the individual and typically involve a
combination of drug and behavioural therapy. Treatment of drug addiction is
usually a long, multi-stage process. Encouragingly, modern drug- dependency
treatment regimes are generally believed to be effective, with 40-70% of
patients successfully recovering from their addiction. Can that same success
be repeated in other addictions. Find out now by simply placing your order for
this business critical report.
What is in the report?
- Statistics of addiction, including potential patient populations and the
economic burden of addiction.
- Drug addiction - Heroin and cocaine addiction treatments, including the
development of vaccinations for cocaine addiction.
- Alcohol addiction - A review of the new products for the treatment of
alcohol addiction, largely those that have been indicated for the treatment of
depression or opioid addiction.
- Smoking addiction - Potentially a huge market. Many health authorities
have placed smoking as a priority. Pfizer have recently launched Chantix,
which is likely to be the first specific treatment for smoking that is an
alternative to the nicotine replacement.
- Gambling addiction - A market that is more potential than current reality.
It faces difficulties in both developing effective treatments and overcoming
cultural perception that gambling is not something that should necessarily be
treated by a pharmaceutical.
- Obesity treatment - Potentially the largest market. The prevalence of
obesity is increasing, with Sanofi-Aventis having recently launched Acomplia.
- Pipeline products - The interest in the addiction markets stems from the
potentially large patient populations and also the large number of products
in the pipeline.
- World market by country region for the specific treatment markets.
Specific drivers and restraints for the addiction treatment markets are
considered.
- Unique research and primary information unavailable elsewhere
Why you must by this report:
The pharmaceutical industry has been seeking the next blockbuster drug, yet it
appears as though these might not be as profligate as they have been in the
past. However, the addiction treatment markets hold promise, particularly for
the development of products for nicotine addiction and the treatment of
obesity. This report analyses the current situation in the market and assesses
the potential of the products that are currently in the development pipeline.
A comprehensive analysis of the addiction treatment market from 2006-2011
outlines the potential of the market. Visiongain expects to see the
development of at least two multi-billion dollar markets. You and your company
should be part of this market, and you could be by placing your order
immediately.
Unique benefits to you when you order this report:
- Full searchable report when you buy the company or corporate editions
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using
harddrive space
- Primary research throughout. You will not find this information anywhere
else
- Report stored in your reading room for ever
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
View Cart
